Quofenix 300 mg powder for concentrate for solution for infusion
Authorisation EU/1/19/1393/001 · A. Menarini Industrie Farmaceutische Riunite S.r.l.
- Licence holder
- A. Menarini Industrie Farmaceutische Riunite S.r.l. (all products →)
- Active substance
- DELAFLOXACIN MEGLUMINE
- Dosage form
- Powder for concentrate for solution for infusion
- Route of administration
- Intravenous use
- ATC codes
- J01MA, J01MA23
- First authorised
- 16/12/2019
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
DELAFLOXACIN MEGLUMINE: supply and approvals
2 authorised products on the HPRA list contain DELAFLOXACIN MEGLUMINE. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1393. It has been authorised for 6 years (since 16 December 2019). The HPRA list does not say whether it is on sale.
Other medicines with DELAFLOXACIN MEGLUMINE in Ireland
1 other product on the HPRA list contains DELAFLOXACIN MEGLUMINE, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Quofenix 450 mg tablets | A. Menarini Industrie Farmaceutische Riunite S.r.l. | Centralised EU authorisation | Not stated |
Other substances in ATC group J01MA
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group J01MA with this product:
Ciprofloxacin (14) · Levofloxacin (9) · Moxifloxacin (2) · Moxifloxacin hydrochloride (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
A. Menarini Industrie Farmaceutische Riunite S.r.l. holds 3 products on the HPRA list, with 2 different active substances; 1 of the products is marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.